Two-compound EBX-001 Eliminates Bacteria Better Than Its Antibiotic Part Alone, Study Reports
cystic fibrosis, News
EBX-001, which consists of two bacteria-fighting compounds, eliminates persistent drug-resistant Pseudomonas aeruginosa in cystic fibrosis patients better than the antibiotic component of the therapy alone, a study reports. The treatment candidate’s developer, EnBiotix, published the ... Read more